The Bethesda System for Reporting Thyroid Cytopathology category of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) includes fine-needle aspiration (FNA) specimens that cannot straightforwardly be classified as benign or malignant. To determine whether morphological subcategorization based on atypia qualifiers and molecular testing could improve malignancy risk stratification of AUS/FLUS patients, this study assessed the correlation between these qualifiers and the molecular alterations commonly harbored by thyroid neo- 
INTRODUCTION
The atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) diagnostic category of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) comprises a heterogeneous set of cases of uncertain interpretation. [1] [2] [3] [4] This diagnostic category reflects either samples that are qualitatively suboptimal because of obscuring blood, poor fixation, or preparation artifacts or samples with quantitatively insufficient morphological changes, that is, samples 1) with a low abundance of microfollicles, 2) with a predominance of H€ urthle cells in a sparsely cellular aspirate or in a well-cellulated aspirate with otherwise a predominance of benign features, or 3) with a focal nuclear atypia of a mild degree but still resembling that associated with papillary thyroid carcinoma (PTC). 1 In these settings, the cytopathologist is reluctant to make a definitive diagnosis and is more comfortable suggesting repeat fine-needle aspiration (FNA). 1 To overcome the inherent limitations of a single interpretive category for these different morphological features and to better tailor patient management, the new edition of TBSRTC (2018) strongly recommends including narrative comments in FNA reports. 5 For example, a description of mild cytologic atypia (CyA) resembling PTC may be more clinically useful than a report of microfollicular architectural atypia (AA) or H€ urthle cell changes (HC). 5, 6 Thus, it has been suggested that diagnostic reports should contain wellcodified descriptive terms (ie, diagnostic qualifiers). 6, 7 AUS/FLUS subcategorization may be even more informative when it is associated with molecular testing. Two recent studies showed that the BRAFV600E mutation, which is virtually always associated with PTC, is more frequently associated with CyA than other qualifiers, and this is in accordance with the high risk of malignancy (ROM) carried by BRAFV600E. 8, 9 In an attempt to identify other mutations that could be associated with diagnostic qualifiers and thus enrich testing algorithms, we prospectively collected a large number of thyroid FNA specimens diagnosed as AUS/FLUS (n 5 162), subtyped them microscopically according to standardized diagnostic qualifiers, 6 and tested them with a 7-gene panel 
MATERIALS AND METHODS
Our institution is a large referral center for thyroid FNA where 3 board-certified cytopathologists, on a rotation basis, perform the FNA procedure under ultrasound guidance. FNA samples are smeared, Diff-Quik-stained, and evaluated on site. For each nodule, 1 to 2 passes are usually taken, and 1 smear is prepared from each pass. The final sign-out is based on TBSRTC criteria. 10 To limit subjective diagnostic variability in reporting AUS/FLUS cases, we have introduced an intra-institutional second-opinion diagnosis strategy. 11 Briefly, before the final sign-out, when an AUS/FLUS diagnosis is proposed by one of the boardcertified cytopathologists (C.B., E.V., or M.D.), the slides are reviewed on a multiheaded microscope by a senior cytopathologist (G.T.) to verify the provisional evaluation.
From March 2016 to January 2017, thyroid FNA was performed 3780 times at our center, and 162 AUS/ FLUS diagnoses (4.2%) were recorded. Since the adoption of TBSRTC criteria at our center, we have used wellcodified short descriptive terms (diagnostic qualifiers) in the AUS/FLUS final sign-out. In brief, as shown in Table  1 , the qualifier CyA refers to cases of mild, focal features suggestive of PTC; AA and HC refer to smears with a scattered or low prevalence of microfollicles or H€ urthle cells, respectively; CyA plus AA refers to cases with both CyA and AA; RC refers to cases of prominent regressive changes such as cyst-lining cells; and AR refers to cases of preparation artifacts. Finally, in AUS/FLUS cases with a mild atypical lymphoid infiltrate, we usually recommend FNA repetition for flow cytometry. Demographic data and nodule size are also recorded.
Since March 2016, we have performed a 7-gene test on all AUS/FLUS thyroid FNA samples, and we include the molecular test results in the final diagnostic report. Briefly, during the FNA procedure, besides the preparation of the smear for the microscopic evaluation, we suspend an aliquot of the aspirated material into a vial of nuclease-free water (Invitrogen Ambion; Thermo Fisher, Waltham, Massachusetts). The vial is stored at -208C until the final cytological diagnosis is available. In case of a diagnosis of AUS/FLUS, the DNA and the RNA are simultaneously extracted with the AllPrep DNA/RNA Kit (Qiagen). The nucleic acid extracted from the vial is analyzed with a realtime polymerase chain reaction (RT-PCR)-based 
Statistical Analysis
The statistical analysis was performed with the Matlab statistical toolbox (version 2008; MathWorks, Natick, Massachusetts) under a 32-bit Windows OS environment. The multiple-comparison chi-square test was used to identify significant differences among percentages. When the result of the chi-square test was significant (P < .05), a residual analysis with the Z test was performed to calculate the frequency of the genomic alteration among the AUS/FLUS qualifiers. The chi-square test with Yates correction and Fisher's exact test were performed to evaluate differences in the proportions and percentages of AUS/FLUS qualifiers with and without genomic alterations. A P value < .05 was considered statistically significant.
RESULTS

Frequency of AUS/FLUS Morphologic Qualifiers
From March 2016 to January 2017, thyroid FNA was performed 3780 times at our center. One hundred sixty-two of these samples (4.3%) were diagnosed as AUS Table 1 . Briefly, the age of the patients ranged from 20 to 83 years (mean, 50 years), the majority were female (75.3%), and the nodule size ranged from 6 to 43 mm (mean, 16.8 mm).
AUS/FLUS Qualifiers and the 7-Gene Test
The distribution of genomic alterations among the different AUS/FLUS qualifiers is summarized in Table 2 and is detailed in Supporting Table 1 . Genomic alterations were identified in only 37 of 162 cases (22.8%; P < .0001; Table  2 ). There were no cases of multiple mutations. Most AUS/ FLUS diagnoses associated with genomic alterations (26 of 37 cases [70.3%]; P < .0001) were either NRAS-mutated (14 of 26) or HRAS-mutated (12 of 26 [46.2%]). Six of the 162 cases (3.7%) carried the BRAFV600E point mutation, whereas 3 (1.9%) and 1 featured PAX8/PPARg and RET/ PTC1 rearrangements, respectively. In 1 case (case 27; Fig.  1A ), the RT-PCR amplification curve of the BRAFV600E mutation probe revealed a cycle threshold and a shape of uncertain interpretation (Fig. 1B) . We verified this result by sequencing BRAF exon 15 on a next-generation sequencing platform (Ion Torrent Personal Genome Machine; Thermo Fisher) as described elsewhere. 12 The sequence of BRAF exon 15 contained a BRAFK601E mutation. The mutation-positive AUS/FLUS cases were more frequently subclassified with the CyA qualifier (14 of 37 [37.84%]) than the mutation-negative AUS/ FLUS cases (20 of 125 [16.00%]; P < .0084; Table 2 ). In particular, all the BRAFV600E point mutations retrieved in the AUS/FLUS FNA cases (n 5 6) were associated with this specific AUS/FLUS qualifier (P < .0001; Table 3 and Fig. 2) .
The AUS/FLUS qualifiers associated with RAS mutations (H-N-KRAS) were, in order of frequency, HC (11 of Figs. 3 and 4) . Similarly, the 3 PAX8/PPARg rearrangements occurred in AUS/FLUS cases designated as AA, CyA, and CyA plus AA, respectively (Table 3 ). The RET/PTC and BRAFK601E alterations occurred in an AUS/FLUS case of CyA and in an AUS/FLUS case of CyA plus AA (Table 3) .
Because of the prospective nature of this study and the short observation time (range, 3-15 months; mean, 8.3 months), histological follow-up was available for only 13 cases. As shown in Table 4 , 9 cases harboring a mutation had a matched histology. In particular, all 3 BRAFV600E-mutated AUS/FLUS samples with CyA were diagnosed as PTC on histology. Conversely, only 2 of the 6 RASmutated samples with available histological outcomes, one with AA and the other with CyA plus AA, were malignant (Table 4) . Finally, only 1 of the 4 mutation-negative AUS/ FLUS cases with AA was diagnosed as follicular carcinoma (Table 4) .
DISCUSSION
The application of TBSRTC criteria for reporting thyroid cytopathology has improved the reproducibility of the FNA diagnosis of thyroid nodules, and it enables cytologists to recommend a conservative or surgical approach according to the ROM of each TBSRTC class. 1 However, up to 30% of thyroid FNA samples are classified as indeterminate on the basis of morphology alone. Depending on the author, various diagnoses are included in the indeterminate category: AUS/FLUS and follicular neoplasm/ suspicious for follicular neoplasm (FN/SFN) only or AUS/ FLUS and FN/SFN plus the suspicious for malignancy (SM) diagnostic category. 2 The FN/SFN and SM diagnostic classes have intermediate (15%-30%) to high ROMs (60%-75%) that warrant diagnostic lobectomy in the former case and oncologic thyroidectomy in the latter case. The AUS/FLUS category has a more variable ROM. Indeed, it includes low-risk cases that could be managed with follow-up plus repeat FNA, as recommended by TBSRTC, and high-risk nodules that could be more appropriately triaged for surgery. To this end, AUS/FLUS subcategorization based on diagnostic qualifiers carrying different ROMs could help to personalize the management of these patients. 1 In fact, AUS/FLUS cases featuring CyA have been reported to have a higher ROM, 6 whereas AA and HC qualifiers carry a lower ROM and are more frequently benign on histology. 6, 8, 9 Little is known about the impact of molecular diagnosis on AUS/FLUS subcategorization. According to preliminary data, AUS/FLUS CyA cases are significantly associated with the BRAFV600E point mutation, 8, 9 whereas the molecular landscape of other AUS/FLUS subcategories is still unexplored. The data prospectively collected during our routine thyroid FNA practice confirm the association between the CyA qualifier and the BRAFV600E mutation. In fact, all 6 BRAFV600E-mutated AUS/FLUS diagnoses were subcategorized as CyA (Table 3) . Moreover, follow-up, which was available in 3 of 6 cases, showed a classic PTC on histology (Table 4) . Thus, our data reinforce the high ROM in the CyA AUS/FLUS subcategory. 6 Interestingly, the only RET/ PTC fusion identified in our samples occurred in a case of CyA-associated AUS/FLUS (Table 3) . Despite the high specificity of BRAFV600E and RET/PTC as markers of malignancy, 13 the clinical usefulness of the 7-gene test we used is limited by the low specificity and low positive predictive value of RAS and RAS-like mutations (PAX8/PPARg and BRAFK601E) because these mutations are also detected in such benign thyroid nodules as follicular adenomas. [14] [15] [16] In addition, the indolent encapsulated PTC follicular variant recently reclassified as a low-risk neoplasm (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]) accounts for a large proportion of RAS-mutated nodules. 17 However, it remains to be established whether mutation-positive adenomas and NIFTP are follicular-patterned in situ carcinomas and should be considered as true-positives in the evaluation of the positive predictive value of the 7-gene test. 13, 18, 19 To evaluate the potential impact of NIFTP on this series, we reviewed the available histology of benign samples originally classified as follicular adenomas, but none of them met the criteria for an NIFTP diagnosis. 19 Unfortunately, surgical follow-up was available for only 13 patients. In fact, at our institution, we have a facility dedicated to the ultrasound-guided FNA of thyroid nodules that serves patients referred from a different part of South Italy. However, not all patients with a cytological or molecular diagnosis (eg, BRAFV600E) that recommends a surgical approach choose to be treated at our institution (eg, patients may prefer private/community hospitals near them). We argue that these patients underwent surgery outside our institution, and we were not able to correlate the molecular findings with the histological outcomes. This represents a limitation of our study, although it reflects our local practice.
The lack of specificity of RAS and RAS-like mutations is reflected by the wide distribution of the latter genomic alterations among the AUS/FLUS qualifiers (Table 3 ). In particular, although RAS-mutated cases were more frequently retrieved in AUS/FLUS cases featuring HC (11 of 26 [42.31%]) and AA (6 of 26 [23.08%]), they were not significantly associated with a specific qualifier (Table 3 ). This is in keeping with the available histological follow-up for RAS-mutated AUS/FLUS, in which only 2 of 6 cases had a malignant outcome (Table 4) . Notably, 1 AA-associated AUS/FLUS diagnosis was a follicular carcinoma, and the other, which featured both CyA and AA, was a follicular variant of PTC.
Lastly, different qualifiers with different ROMs may harbor different mutations, which may have different positive predictive values. Consequently, the cytopathologist must integrate the AUS/FLUS qualifiers and molecular data in a hybrid morphologic and molecular AUS/FLUS subclassification system that can be more efficient in triaging patients for surgery or clinical follow-up.
In conclusion, BRAF and N-H-KRAS mutations and RET/PTC1, RET/PTC3, and PAX8/PPARg fusions are associated with different AUS/FLUS classifiers that reflect the different biological and clinical natures of the molecular alterations detected by the 7-gene test and the AUS/ FLUS subcategories. Further investigations are warranted to develop a hybrid morphological and molecular stratification of the AUS/FLUS diagnostic class to improve the clinical management of these patients.
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